Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.

Saved in:
Bibliographic Details
Title: Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.
Authors: Boreel C; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584CX, the Netherlands. Electronic address: c.d.m.boreel-2@umcutrecht.nl., de Ruijter J; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584CX, the Netherlands., van Not O; Department of Dermatology, Leiden University Medical Centre, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Bloem M; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, Leiden 2333ZC, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands., Been L; Department of Surgical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, Groningen 9713GZ, the Netherlands., Aarts M; Department of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, P. Debyelaan 25, Maastricht 6229 HX, the Netherlands., van den Berkmortel F; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen 6162BG, the Netherlands., Blank C; Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands; Division of Immunology, Amsterdam, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands; Department of Hematology and Oncology, University Clinic Regensburg (UKR), Regensburg, Germany; Division of Melanoma and Sarcoma, European Institute of Oncology (IEO), Milano, Italy; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Boers-Sonderen M; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen 6525GA, the Netherlands., Bonenkamp H; Department of Surgery, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen 6525GA, the Netherlands., de Groot JW; Isala Oncology Centre, Isala, Dokter van Heesweg 2, Zwolle 8025AB, the Netherlands., Grünhagen D; Department of Surgical Oncology, Erasmus Medical Centre, Dr. Molewaterplein 40, Rotterdam 3015GD, the Netherlands., Haanen J; Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands; Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 21, Lausanne CH-1011, Switzerland; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden 2333ZA, the Netherlands., Hilde Jalving M; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, Groningen 9713GZ, the Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede 7512KZ, the Netherlands., Rikhof B; Department of Internal Medicine, Frisius MC, Henri Dunantweg 2, Leeuwarden 8934AD, the Netherlands., Boer MS; Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda 4818CK, the Netherlands., van der Veldt A; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Dr. Molewaterplein 40, Rotterdam 3015GD, the Netherlands., Simkens L; Department of Internal Medicine, Maxima Medical Centre, De Run 4600, Eindhoven 5504DB, the Netherlands., Wouters M; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, Leiden 2333ZC, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden 2333ZA, the Netherlands., van den Eertwegh F; Department of Medical Oncology, Amsterdam UMC, VU University Medical Centre, Cancer Centre Amsterdam, De Boelelaan 1118, Amsterdam 1081HZ, the Netherlands., Suijkerbuijk K; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584CX, the Netherlands.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 Jun 21; Vol. 244, pp. 116889. Date of Electronic Publication: 2026 Jun 21.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2026.116889